ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men
Initial Investment to Help Research, Identify and Apply Innovative Solutions in Baltimore, Maryland and Jackson, Mississippi - Two of the Cities Hardest Hit by HIV/AIDS
New funding builds on a longstanding partnership to help Kenyans receive quality care
ABBOTT PARK, Ill., Feb.
Camps help hundreds of children with diabetes learn lifelong disease management skills
Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis
Primary Efficacy Analysis Demonstrates Clinical Equivalence
THOUSAND OAKS, Calif., Feb.
Merck's Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
Only prescription medication in U.S.
Editor Note: For more information about this release, please scroll to bottom.
LONDON, February 2, 2015